Using Sugammadex to speed up recovery after throat surgery
Use of Sugammadex for Reversal of Paralysis in Microlaryngoscopy
This study is testing if Sugammadex can help people recover faster from throat surgery by speeding up the process of waking up from anesthesia compared to standard methods.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 84 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | West Virginia University Academic / other |
| Locations | 1 site (Morgantown, West Virginia) |
| Trial ID | NCT03111121 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the use of Sugammadex for reversing muscle paralysis at the end of microlaryngoscopy and rigid bronchoscopy procedures. It is a prospective, randomized, single-blinded study conducted at a single center. The primary goal is to determine if Sugammadex can reduce the time to extubation compared to traditional reversal methods. Secondary outcomes include assessing surgical conditions, hemodynamic stability, and overall recovery times in the post-anesthesia care unit (PACU).
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 years or older undergoing microlaryngoscopy or rigid bronchoscopy with ASA physical status I-III.
Not a fit: Patients with known neuromuscular diseases, severe renal impairment, or contraindications to the study medications will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to faster recovery times and improved safety for patients undergoing airway procedures.
How similar studies have performed: Other studies have shown promising results with Sugammadex in similar contexts, indicating potential for success in this trial.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Microlaryngoscopy or rigid bronchoscopy for vocal cord and tracheal procedures Age 18 years or older, ASA physical status I-III Ability to give written informed consent. Exclusion Criteria: Known or suspected neuromuscular disease/pre-existing weakness, Creatinine clearance less than 30 ml/min Bradycardia of less than 40 beats/min, Pregnancy, breast feeding women Known or suspected allergy to BRIDION® (sugammadex), neostigmine or rocuronium. Patients with contraindications towards sugammadex, neostigmine or rocuronium Patients included in another trial within the last 30 days Patients with legal guardians or surrogate decision making Patients who refuse to use non-hormonal contraceptive method or back-up method of contraception (such as condoms and spermicides) for the next 7 days if receiving sugammadex. -
Where this trial is running
Morgantown, West Virginia
- WVU Healthcare Ruby Memorial Hospital — Morgantown, West Virginia, United States (Recruiting)
Study contacts
- Study coordinator: Pavithra Ranganathan, MD
- Email: ranganathanp@wvumedicine.org
- Phone: 304-598-4929
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.